Abstract
The study objective was to compare changes in all-cause and painful diabetic peripheral neuropathy (pDPN)-related healthcare costs in patients initiating treatment with pregabalin (PGB) and duloxetine (DLX) in real-world settings. Patients (318 years) initiating PGB or DLX between 6/1/07-12/31/08 were identified from a large US managed care plan database. Those with 3 1 medical claim with: (1) primary or secondary ICD-9-CM code of 357.2; or (2) primary code of 249.xx or 250.xx plus 337.1, 354.4, 354.5, 354.8, 354.9, 355.7x, 355.8, 355.9 or 356.9 on the same claim were considered to have pDPN.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
